Related Experiment Video
Updated: Dec 10, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing
Thomas Severin1, Solange Corriol-Rohou2, Christina Bucci-Rechtweg3
1Global Drug Development, Novartis Pharma AG, Novartis Campus, 4002, Basel, Switzerland. thomas.severin@novartis.com.
Abstract:
The article How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement, written by Thomas Severin et al. was originally published electronically on the publisher's internet portal on February 6, 2020 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on April 22, 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Discovery: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Preclinical Development: Overview

